• Miscellaneous neurodegenerative disorders

Cuvposa Generic Name & Formulations

General Description

Glycopyrrolate 1mg/5mL; oral soln; cherry-flavored.

Pharmacological Class


How Supplied



Generic Availability


Cuvposa Indications


To reduce chronic severe drooling in patients 3–16yrs of age with neurologic conditions associated with problem drooling (eg, cerebral palsy).

Cuvposa Dosage and Administration


Not applicable.


<3yrs: not recommended. Use accurate measuring device. Take on empty stomach. 3–16yrs: initially 0.02mg/kg 3 times daily; may titrate in increments of 0.02mg/kg every 5–7 days based on response and adverse reactions. Max 0.1mg/kg 3 times daily, not to exceed 1.5–3mg per dose based upon weight. See full labeling.

Cuvposa Contraindications


Conditions that preclude anticholinergic therapy (eg, glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon, myasthenia gravis). Concomitant potassium chloride solid oral dosage forms (passage through GI may be arrested or delayed).

Cuvposa Boxed Warnings

Not Applicable

Cuvposa Warnings/Precautions


Monitor for constipation esp. within 4–5 days of initial dosing or after dose increase. Discontinue if incomplete mechanical intestinal obstruction develops (diarrhea may be early symptom). Autonomic neuropathy. Renal impairment. Ulcerative colitis (esp. large doses). Hyperthyroidism. Cardiovascular disease. CHF. Arrhythmias. Tachycardia. Hypertension. Hiatal hernia associated with reflux esophagitis. Avoid high environmental temperature. Pregnancy (Cat.C). Nursing mothers.

Cuvposa Pharmacokinetics

See Literature

Cuvposa Interactions


See Contraindications. May potentiate digoxin slow dissolution oral tabs; monitor and consider using other forms (eg, elixir, caps). Additive antichlolinergic effects with amantadine; consider reducing glycopyrrolate dose. May potentiate atenolol, metformin; consider dose reduction. May antagonize haloperidol (closely monitor or avoid), levodopa (consider increasing dose).

Cuvposa Adverse Reactions

Adverse Reactions

Dry mouth, vomiting, constipation, flushing, nasal congestion; drowsiness, blurred vision, intestinal pseudo-obstruction, mechanical intestinal obstruction.

Cuvposa Clinical Trials

See Literature

Cuvposa Note

Not Applicable

Cuvposa Patient Counseling

See Literature